Tatsuo Miyamura – författare

This volume is composed of chapters that review important fundamental aspects of HCV biology and disease pathogenesis including, for example, the discovery and identification of the HCV genome, early virus-cell interactions including identification of various cellular receptors, HCV gene expression studied using the HCV replicon system, identification and characterization of HCV structural- and non-structural HCV proteins, HCV replication in cultured cells, and host factors involved in viral replication. This volume also contains chapters dealing with immunity to HCV infection and pathogenesis. This is particularly important in understanding hepatitis C because HCV infection alone is not cell lytic. Mechanisms underlying the persistent nature of HCV infection are also discussed in these chapters. Many of the authors published articles that were listed among the “top 10 papers” published in the 24 years since HCV was discovered in 1989. Their citations are above 1,000 (Web of Science). The authors describe the background and significance of their contributions to the field in the context of findings from other research groups.

This book helps scientists, clinicians and other interested individuals understand recent clinical advances and challenges for the future. It covers many basic aspects of the pathogenesis of chronic hepatitis C, HCV infections in particular populations, approaches to therapy, and prevention and control of HCV Infection. The book provides a succinct review of the large amount of data generated by multiple groups over the past two decades that has revealed the natural history of HCV infection. Similarly, it summarizes current understanding of the origins of HCV-associated hepatocellular carcinoma, cirrhosis and hepatic fibrosis. Extra-hepatic manifestation and metabolic disorders related to HCV infection are described. In this volume, these clinically important aspects of HCV infection are comprehensively described. Highlights are description of newly developed direct- acting antivirals. The authors represent a worldwide distribution of leaders in the field reflecting the global nature of HCV infection. Based on recent data concerning the genetic- and geographical diversity of HCV, and increased global disease burden of HCV infection, challenges for global control of HCV infections are described.